Related Experiment Video

Updated: Apr 19, 2026

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

8.8K

Anticancer agents targeted to sirtuins

Tomohiro Kozako1, Takayoshi Suzuki2, Makoto Yoshimitsu3

  • 1Department of Biochemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan. kozako@fukuoka-u.ac.jp.

Molecules (Basel, Switzerland)
|December 9, 2014
PubMed

Insights

Sirtuins (silent information regulators) are enzymes impacting aging and cancer. This review explores sirtuin modulators as potential cancer therapies, focusing on SIRT1 and SIRT2.

Area of Science:

  • Biochemistry and Molecular Biology
  • Oncology
  • Aging Research

Background:

  • Sirtuins are a class of nicotinamide adenine dinucleotide+-dependent deacetylases with seven isoforms (SIRT1-7).
  • Sirtuin activity influences critical cellular processes including gene expression, aging, and neurodegeneration.
  • Emerging evidence links sirtuins to both anti-aging effects and cancer development, contingent on specific cellular targets and pathways.

Purpose of the Study:

  • To review the role of sirtuins, particularly SIRT1 and SIRT2, as potential therapeutic targets in cancer.
  • To explore the therapeutic potential of small molecule sirtuin modulators in cancer prevention and treatment.
  • To enhance understanding of sirtuin biological functions and molecular mechanisms through modulator studies.

Main Methods:

  • Literature review of studies investigating sirtuin isoforms (SIRT1-7) and their functions.
  • Analysis of research on small chemical compounds that modulate sirtuin activity.
  • Focus on studies examining the link between sirtuins, particularly SIRT1 and SIRT2, and cancer.

Main Results:

  • Sirtuin activity is implicated in diverse biological processes, including aging and age-related diseases.
  • Sirtuins play a dual role in tumorigenesis, potentially promoting or inhibiting cancer depending on context.
  • Sirtuin modulators have proven valuable in elucidating sirtuin functions and mechanisms.

Conclusions:

  • Sirtuins, especially SIRT1 and SIRT2, represent promising targets for novel cancer therapies.
  • Sirtuin modulators offer significant therapeutic potential for both the prevention and treatment of cancer.
  • Further research into sirtuin modulators could lead to innovative anti-cancer strategies.

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.7K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

12.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
19.1K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.3K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
19.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K